Bolt Biotherapeutics, Inc.
BOLT · Price history
Price at last available close
$6.58
+$2.98 (+82.78%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Bolt Biotherapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
How they make money
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through research and development collaborations and licensing agreements. The company focuses on developing its proprietary Immune-Stimulating Antibody Conjugate (ISAC) platform, and its business model relies on achieving development milestones and receiving potential future royalties from partners rather than commercial product sales.
Products & services
The company is developing a pipeline of Immune-Stimulating Antibody Conjugate (ISAC) therapeutics, including its lead clinical candidate BDC-4182, which is currently in a Phase 1 dose escalation trial for gastric and gastroesophageal junction cancer.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed.Source
Strengths
- Proprietary ISAC platform technologySource
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 99.7% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
19
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
20
Poor
Financial Strength
37
Business Quality / Moat
37
Management
0
Growth Quality
0
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
24
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
32/100
Building Historical Record
Model Score 32/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for BOLT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving BOLT's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can BOLT fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does BOLT's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for BOLT to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BOLT's current valuation?
Essential Investment Snapshot
Wall Street Score
19
Opportunity Score
24
Market Cap
$12.7M
P/E Ratio
-0.2
EPS
$-16.00
52-Week High
$7.20
52-Week Low
$3.10
Beta
1.09
Analyst Target
$4.00
Shares Outstanding
1.9M
Total Revenue
$4.7M
Total Debt
$21.6M
Dividend
No current dividend
Liquidation Value / Share
$6.76
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BOLT
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on BOLT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary ISAC platform technology.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party manufacturers for clinical supply.
- −History of operating losses and uncertainty of future profitability.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
19
Sep 9, 2026
Change
Unchanged
Current Score
19
Oct 1, 2026
Category Changes
BOLT score was unchanged.
Projected Score
Projected Score
16
Projected Change
-2.7 points
Preliminary comparable-period financial changes suggest decline of approximately 2.7 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$6.58
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $7.7M | $7.7M | $7.9M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $203K | $1.5M | $0.00 | $61.5M | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $4.5M | $6.2M | $7.7M | -$53.7M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $21.3M | $28.5M | $57.5M | $61.5M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $11.7M | $13.8M | $18.5M | $22.5M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $33.8M | $40.8M | $80.7M | $22.5M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$27.8M | -$31.9M | -$66.5M | -$67.3M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$29.3M | -$34.6M | -$73.0M | -$76.2M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$28.7M | -$33.4M | -$63.1M | -$69.2M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$28.7M | -$33.4M | -$63.1M | -$69.2M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-16.00 | $-17.85 | $-1.65 | $-1.83 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 1.69M | 1.87M | 1.91M | 1.89M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 1.69M | 1.87M | 1.91M | 1.89M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$5000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$4.57
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-10.6%
Cash Change
+33.9%
Margin Change
-153925.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. Pressure indicators included revenue growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 99.7%. EPS increased 2.5%. Cash increased 33.9%. Total debt declined 10.6%. Net income margin declined by 153925.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
Bolt Biotherapeutics (NASDAQ:BOLT) VP Sarah Nemec Sells 4,077 Shares
Bolt Biotherapeutics (NASDAQ:BOLT) COO Grant Yonehiro Sells 4,909 Shares of Stock
Rumor Mill · BOLT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial